mCMX110
mCMX110 is an orally active SARS-CoV-2 main protease inhibitor with an IC50 of 35 nM. mCMX110 inhibits SARS-CoV-2 infection. SARS-CoV-2 mCMX110 can be used for the research of SARS-CoV-2 infection.
For research use only. We do not sell to patients.
- CAS No.: 2883773-06-4
- Formula: C22H38N4O6
- Molecular Weight:454.56
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
mCMX110 inhibits wild-type SARS-CoV-2 infection in HeLa-ACE2 cells with an EC50 of 97 nM, EC90 of 241 nM, and LLE_EC90 of 6.8, with no cytotoxicity at concentrations >40 μM[1].
mCMX110 inhibits Alpha variant SARS-CoV-2 infection in HeLa-ACE2 cells with an EC90 of 339 nM and Omicron variant SARS-CoV-2 infection with an EC90 of 255 nM[1].
mCMX110 (48 h) inhibits HCoV-OC43 infection in HCT-8 cells with an EC90 of 5.63 μM, with no cytotoxicity at concentrations >30 μM[1].
mCMX110 (120 h) inhibits HCoV-229E infection in MRC-5 pd25 cells with an EC90 of 930 nM, with no cytotoxicity at concentrations >30 μM[1].
mCMX110 does not inhibit CYP isoforms 1A2, 2C19, 2C9, 2D6, or 3A4 at concentrations >50 μM[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:CD1 mice; Sprague-Dawley rats; beagle dogs[1]
-
Dosage:30, 50 mg/kg (CD1 mice, single dose); 30 mg/kg (Sprague-Dawley rats, single dose); 300 mg/kg (Sprague-Dawley rats, twice daily); 10, 100 mg/kg (beagle dogs, single dose); 250 mg/kg (beagle dogs, twice daily); 125 mg/kg/dose (beagle dogs, twice daily for 5 days); 100-300 mg/kg/dose (Sprague-Dawley rats, twice daily for 5 days)
-
Administration:p.o.; single dose; twice daily; twice daily for 5 days
-
Result:Reached oral bioavailability of 18% in CD1 mice, 10-12% in Sprague-Dawley rats, and 44-79% in beagle dogs.
Achieved plasma clearance (IV) of 83.7 mL/min/kg in CD1 mice, 15.3 mL/min/kg in Sprague-Dawley rats, 17.2 mL/min/kg in beagle dogs, and 32.6 mL/min/kg in cynomolgus monkeys.
Attained volume of distribution (IV, Vss) of 0.78 L/kg in CD1 mice, 1.3 L/kg in Sprague-Dawley rats, 0.93 L/kg in beagle dogs, and 1.5 L/kg in cynomolgus monkeys.
Exceeded the SARS-CoV-2 EC90 threshold (110 ng/mL) in plasma concentrations after oral dosing across all tested species, with good dose-proportional exposure in rats and dogs.
Caused no adverse effects in beagle dogs dosed at 125 mg/kg/dose twice daily for 5 days.
Showed no prohibitive findings in Sprague-Dawley rats dosed at 100-300 mg/kg/dose twice daily for 5 days.
Chemical Information
-
CAS No. 2883773-06-4
-
Molecular Weight 454.56
-
Formula C22H38N4O6
-
SMILES
O=C(NC(C)(C)C)C(N[C@H](C(N[C@H](C(CO)=O)C[C@H]1C(NCCC1)=O)=O)CC(C)(C)C)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
mCMX110 Related Classifications
HY-184171 Related Classifications
Powered by Bioz